

## DAFTAR PUSTAKA

- Braga Lemos, M. *et al.* (2021) 'Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis', *European Journal of Haematology*. John Wiley and Sons Inc, pp. 3–23. Available at: <https://doi.org/10.1111/ejh.13619>.
- Chen, S. *et al.* (2007) 'Treatment of myelodysplastic syndrome with cyclosporin A', *International Journal of Hematology*, 85(1), pp. 11–17. Available at: <https://doi.org/10.1532/IJH97.A10513>.
- Dotson, J.L. and Lebowicz, Y. (2022) *Myelodysplastic Syndrome - StatPearls - NCBI Bookshelf*. StatPearls.
- Fattizzo, B. *et al.* (2023) 'Use of steroids in the management of low-risk myelodysplastic syndromes with autoimmune features', *Blood Transfusion*, 21(5), pp. 452–460. Available at: <https://doi.org/10.2450/2022.0184-22>.
- Garcia-Manero, G. (2023) 'Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management', *American Journal of Hematology*, 98(8), pp. 1307–1325. Available at: <https://doi.org/10.1002/ajh.26984>.
- Gupta, S. *et al.* (2023) 'Association between transfusion status and clinical and economic outcomes in patients with myelodysplastic syndromes from the physicians' perspective', *Cancer Reports*, 6(1). Available at: <https://doi.org/10.1002/cnr2.1680>.
- Hong, M. and He, G. (2017) 'The 2016 revision to the World Health Organization classification of myelodysplastic syndromes', *Journal of Translational Internal Medicine*, 5(3), pp. 139–143. Available at: <https://doi.org/10.1515/jtim-2017-0002>.
- Jiang, Y. *et al.* (2021) 'Asian population is more prone to develop high-risk myelodysplastic syndrome, concordantly with their propensity to exhibit high-risk cytogenetic aberrations', *Cancers*, 13(3), pp. 1–23. Available at: <https://doi.org/10.3390/cancers13030481>.
- Marques, F.K. and Sabino, A. de P. (2022) 'Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment', *Biomedicine and Pharmacotherapy*. Elsevier Masson s.r.l. Available at: <https://doi.org/10.1016/j.biopha.2022.113905>.

- Parikh, A.R., Olnes, M.J. and Barrett, A.J. (2012) ‘Immunomodulatory Treatment of Myelodysplastic Syndromes: Antithymocyte Globulin, Cyclosporine, and Alemtuzumab’, *Seminars in Hematology*, 49(4), pp. 304–311. Available at: <https://doi.org/10.1053/j.seminhematol.2012.07.004>.
- Shimamoto, T. *et al.* (2003) ‘Cyclosporin A therapy for patients with myelodysplastic syndrome: Multicenter pilot studies in Japan’, *Leukemia Research*, 27(9), pp. 783–788. Available at: [https://doi.org/10.1016/S0145-2126\(03\)00008-0](https://doi.org/10.1016/S0145-2126(03)00008-0).
- Stahl, M. *et al.* (2018) ‘The use of immunosuppressive therapy in MDS: Clinical outcomes and their predictors in a large international patient cohort’, *Blood Advances*, 2(14), pp. 1765–1772. Available at: <https://doi.org/10.1182/bloodadvances.2018019414>.
- de Swart, L. *et al.* (2020) ‘Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes’, *Haematologica*, 105(3), pp. 632–639. Available at: <https://doi.org/10.3324/haematol.2018.212217>.
- Wood, E.M. and Mcquilten, Z.K. (2020) *CHRONIC TRANSFUSION SUPPORT: CHALLENGING CASES Outpatient transfusions for myelodysplastic syndromes*.
- Yamada, T. *et al.* (2003) ‘Immunosuppressive therapy for myelodysplastic syndrome: Efficacy of methylprednisolone pulse therapy with or without cyclosporin A’, *Journal of Cancer Research and Clinical Oncology*, 129(8), pp. 485–491. Available at: <https://doi.org/10.1007/s00432-003-0477-z>.